Skip to content

Recursion

Recursion uses an AI-native drug discovery platform to decode cellular biology and develop new medicines for cancers and rare diseases.

60

Overview

Recursion is an AI drug discovery company that uses a platform called Recursion OS to decode cellular biology and develop new medicines for cancers and rare diseases. Founded more than a decade ago, the company aims to reduce the 90% failure rate of traditional drug discovery by training artificial intelligence on images of cells to understand the cellular disruptions that drive disease.

The Recursion OS Platform

At the core of Recursion's approach is the Recursion OS, a drug discovery and development platform that integrates wet-lab automation and machine learning. The system runs up to 2 million weekly experiments, generating a proprietary dataset of over 50 petabytes. This dataset connects biology, generative de novo chemistry, and translational clinical tools, creating a continuous learning loop that systematically de-risks drug discovery. The platform is driven by bilingual teams of scientists and technologists who operate automated labs as an AI-native data factory.

Pipeline and Therapeutic Focus

Recursion's pipeline includes potential first-in-class and best-in-class treatments for conditions with high unmet need, such as aggressive cancers and rare diseases. The company has demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages. One example is REC-3565, a selective MALT1 inhibitor for relapsed or refractory B-cell lymphomas, which has entered Phase 1 clinical testing.

Partnerships and Collaboration

Recursion collaborates with pharmaceutical and technology leaders through strategic partnerships. These alliances accelerate the discovery of new medicines and expand the potential impact on patients. By combining computational titans and next-generation data partnerships, Recursion enhances its capabilities in generative AI for pharma, positioning itself among the top AI drug discovery companies in the industry.

Data-Driven Approach to Drug Discovery

The company leverages patient data to inform its AI drug discovery efforts. By analyzing cellular images and other biological data, Recursion's platform identifies novel insights that guide precision design of potential medicines. This data-driven approach aims to bring better medicines to patients faster, addressing the vast unknown biological space that drives disease.

Clinical Progress and Industry Impact

Recursion's clinical progress includes advancing its pipeline into human trials. The first patient has been dosed in a Phase 1 study of REC-3565, marking a step forward in developing treatments for B-cell lymphomas. The company's work has attracted attention in the broader race to bring AI-discovered drugs to market, as highlighted by media coverage of the multibillion-dollar efforts in this field.

Mission and Vision

Recursion was founded on the idea that images of cells could train artificial intelligence to understand disease biology. The mission is to decode biology to radically improve lives. By combining physical automation and machine learning models, Recursion aims to systematically de-risk drug discovery and deliver better medicines through novel insights and precision design.

Core features

  • AI engine that analyzes cellular images to identify disease-driving disruptions
  • Recursion OS platform integrating wet-lab automation and machine learning
  • Runs up to 2 million weekly experiments to build a 50+ petabyte proprietary dataset
  • Connects biology, generative de novo chemistry, and translational clinical tools
  • Advanced pipeline of potential first-in-class and best-in-class treatments
  • Strategic partnerships with pharmaceutical and technology leaders

Use cases

  1. 1Discovering novel medicines for aggressive cancers and rare diseases
  2. 2Reducing the 90% failure rate of traditional drug discovery
  3. 3Accelerating hit identification to IND-enabling studies
  4. 4De-risking drug discovery through systematic data analysis
  5. 5Partnering with pharmaceutical companies to expand drug pipelines

Strengths and things to check

Strengths

  • Demonstrated improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies
  • Proprietary dataset of over 50 petabytes from up to 2 million weekly experiments
  • End-to-end drug discovery and development engine with automated labs
  • Strategic partnerships with industry leaders enhance capabilities

Things to check

  • The platform's complexity may require specialized expertise to utilize effectively
  • Reliance on large-scale data and automation could pose integration challenges
  • Clinical success rates for AI-discovered drugs remain unproven at scale

Pricing

Subscription pricing is not listed.

Basic information

Added
Oct 10, 2026
Platforms
Web
Chinese & English
Not marked
API
Marked as supported
Self-hosting
Not marked
Best for
Pharmaceutical researchers, biotech investors, and partners seeking AI-driven drug discovery capabilities.
Information updated
Oct 16, 2026
Website status
Checking
Corrections · Privacy · Data requests?
Contact us

Features, pricing and availability may change. Always verify details on the official website. Maintained by steven · Last updated Oct 16, 2026 →

Related tools

All categories

Nabla

Enterprise Grade

Nabla is a clinical AI layer that captures patient-clinician conversations and generates structured notes, dictation, and coding suggestions inside Epic and major EHRs.

Enterprise GradeAPI Available
60
Free TierSOC 2
View details

Wysa

Enterprise Grade

Wysa is an AI-powered mental health support platform that offers safe, clinically backed care for individuals, teams, and health systems. It provides self-help, guided referral, and between-session support through an always-available, anonymous chat interface.

Enterprise GradeAPI Available
60
Free Tier
View details